Kazia Therapeutics (KZIA) Income from Continuing Operations (2009 - 2017)
Kazia Therapeutics (KZIA) posted Income from Continuing Operations of 8164905.08 for Q2 2017, up 10.45% on a QoQ basis from 9118175.3 in Q4 2016, and up 10.04% year-over-year from 7419931.29 in Q2 2016.
Kazia Therapeutics (KZIA) Income from Continuing Operations (2009 - 2017) Analysis & Trends
Kazia Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 8164905.08 for Q2 2017.
- Quarterly Income from Continuing Operations rose 10.04% year-over-year to 8164905.08 in Q2 2017, while the trailing twelve-month figure through Jun 2017 was 31617304.24 (down 42.37% YoY) and the FY2025 annual result came in at 13258248.17, up 24.13% from the prior year.
- Income from Continuing Operations was 8164905.08 for Q2 2017 at Kazia Therapeutics, up from 9118175.3 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1399079.36 in Q4 2013 and bottomed at 9118175.3 in Q4 2016.
- A 5-year average of 6581830.96 and a median of 7319753.62 in 2014 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2014 — Income from Continuing Operations slumped 362.78% — and 2015, when it climbed 18.79%.
- Kazia Therapeutics' Income from Continuing Operations stood at 1399079.36 in 2013, then tumbled by 362.78% to 6474602.17 in 2014, then increased by 18.79% to 5258056.02 in 2015, then plunged by 73.41% to 9118175.3 in 2016, then climbed by 10.45% to 8164905.08 in 2017.
- Business Quant data shows KZIA's Income from Continuing Operations at 8164905.08 in Q2 2017, 9118175.3 in Q4 2016, and 9076167.85 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Kazia Therapeutics | 4.11 Mn | 4.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -8.16 Mn |
| Dec 31, 2016 | -9.12 Mn |
| Jun 30, 2016 | -9.08 Mn |
| Dec 31, 2015 | -5.26 Mn |
| Dec 31, 2014 | -6.47 Mn |
| Dec 31, 2013 | -1.40 Mn |
| Dec 31, 2012 | -1.53 Mn |
| Oct 8, 2012 | -11.38 Mn |
| Dec 31, 2011 | 15.11 Mn |
| Dec 31, 2010 | -5.15 Mn |
| Dec 31, 2009 | -5.81 Mn |